The 1 AI Stock I'd Put in a Time Capsule and Open in 2036

Absci is presented as a speculative AI-biotech platform that designs protein drugs in silico before lab testing, with partnerships from Merck and Owkin cited as validation of its technology. The article highlights upside from potential clinical success, royalties, and platform scalability, but also stresses high execution risk, dilution risk, and the long timeline to 2036. Overall tone is constructive but cautious, with the piece functioning more as long-term investment commentary than a near-term catalyst.

Analysis

The market is likely underpricing Absci as a compounding R&D option rather than a single-asset biotech. The real lever is not whether any one partnered program works, but whether the platform can repeatedly convert computational designs into validated candidates faster and cheaper than traditional discovery workflows; that shifts the economic value from milestone revenue to a higher-margin, multi-shot engine. If that loop keeps working, the appropriate multiple should expand before any commercial drug actually launches, because the asset being valued is a shrinking-cycle-time discovery stack, not a binary pipeline.

The second-order effect is pressure on legacy discovery budgets. If large pharmas can outsource early target-to-lead work to AI-native platforms and preserve internal chemistry/biology teams for later-stage validation, vendors with weaker data generation loops get squeezed first. That also means the competitive moat is likely in proprietary training data and wet-lab throughput, not model quality alone; any deterioration in candidate success rates or assay bottlenecks would hit the story faster than headline partnership announcements can offset it.

The biggest risk is financing dilution before the platform reaches self-funding scale. In small-cap biotech, the market often rewards story until it is forced to re-rate around cash runway, and that inflection can happen 12-24 months before a true scientific readout. A negative clinical event would hurt, but the more common failure mode is slower-than-expected iteration speed, which compresses the probability-weighted value of both the owned pipeline and partner optionality.

Contrarian angle: the consensus may be too focused on “AI for drugs” as a branding premium and too little on the economics of reproducibility. The upside is real if Absci can demonstrate a durable advantage in hit-to-lead conversion and manufacturability; without that, partnerships become low-quality validation rather than monetizable evidence. The stock likely works best as a long-duration venture-style position only after confirmation of repeatable preclinical wins, not on thesis alone.

Key Decisions for Investors

• Long ABSI only as a small starter position into weakness; treat it as a 12-24 month venture-style optionality trade with asymmetric upside, but cap sizing given dilution and binary clinical risk.
• Use 6-12 month call spreads on ABSI rather than common stock if liquidity allows; this expresses upside from partnership-driven re-rating while limiting capital at risk if financing pressure shows up early.
• Pair trade: long ABSI / short a basket of slower-moving traditional discovery services or tool names exposed to outsourced preclinical spend, to isolate the AI-enabled workflow displacement theme over the next 2-4 quarters.
• Avoid chasing NVDA on this headline; the article is structurally positive for AI adoption, but the second-order read-through is capped for compute and more relevant for biology software/platform names than for chip leadership.
• Watch for a financing or pipeline update within the next 1-2 quarters; if gross cash burn accelerates without a new high-quality partner, trim quickly as the valuation can de-rate faster than operating milestones accrue.